Onfi (Clobazam) Patent Expiration, LOE Window & CMS Spending

Onfi (Clobazam) by Lundbeck: Off-Patent Genericized (AB Competition), 17 AB generics, $104.4M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorLundbeck
FDA Application & PathwayN202067 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors17
2024 CMS Total Public Spend$104.4M
2024 Medicare Part D Spend$31.4M
2024 Medicaid Spend$73.0M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 24.8% 2-yr change)